Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed previously untreated non-small cell lung cancer. If a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study. Neuroendocrine carcinomas are not eligible. Carcinomas with neuroendocrine differentiation are eligible * Patients with stage IA or stage IB \< 4 cm (according to American Joint Committee on Cancer \[AJCC\] 7th edition) are eligible for randomization into arms A and B only. Patients with stage IB \>= 4 cm, IIA, IIB, or IIIA disease (according to AJCC 7th edition) are eligible for randomization into arms A, and B, and for enrollment into arms C and D * Patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor * All patients must have lymph node evaluation of contralateral stations 2 and/or 4 to exclude N3 disease * The patient must be a suitable candidate for surgery, in the opinion of the treating physician * Signed and dated written informed consent must be provided by the patient prior to admission to the study in accordance with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines and to the local legislation * Eastern Cooperative Oncology Group (ECOG) performance status score 0-1 * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L * Hemoglobin \>= 8.0 g/dL * Platelets \>= 100 x 10\^9/L *…